Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

A humanized monoclonal antibody specific for invariant Natural Killer T (iNKT) cells for in vivo depletion.

Scheuplein F, Thariath A, Macdonald S, Truneh A, Mashal R, Schaub R.

PLoS One. 2013 Sep 27;8(9):e76692. doi: 10.1371/journal.pone.0076692. eCollection 2013.

2.

A heat shock protein based polyvalent vaccine targeting HSV-2: CD4(+) and CD8(+) cellular immunity and protective efficacy.

Mo A, Musselli C, Chen H, Pappas J, Leclair K, Liu A, Chicz RM, Truneh A, Monks S, Levey DL, Srivastava PK.

Vaccine. 2011 Nov 3;29(47):8530-41. doi: 10.1016/j.vaccine.2011.07.011. Epub 2011 Jul 19.

PMID:
21767588
3.

B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function.

Serriari NE, Gondois-Rey F, Guillaume Y, Remmerswaal EB, Pastor S, Messal N, Truneh A, Hirsch I, van Lier RA, Olive D.

J Immunol. 2010 Sep 15;185(6):3140-8. doi: 10.4049/jimmunol.0902487. Epub 2010 Aug 6.

4.

PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1.

Ghiotto M, Gauthier L, Serriari N, Pastor S, Truneh A, Nunès JA, Olive D.

Int Immunol. 2010 Aug;22(8):651-60. doi: 10.1093/intimm/dxq049. Epub 2010 Jun 29.

5.

Cosignaling molecules around LIGHT-HVEM-BTLA: from immune activation to therapeutic targeting.

Pasero C, Truneh A, Olive D.

Curr Mol Med. 2009 Sep;9(7):911-27. Review.

PMID:
19860669
6.

A role for HVEM, but not lymphotoxin-beta receptor, in LIGHT-induced tumor cell death and chemokine production.

Pasero C, Barbarat B, Just-Landi S, Bernard A, Aurran-Schleinitz T, Rey J, Eldering E, Truneh A, Costello RT, Olive D.

Eur J Immunol. 2009 Sep;39(9):2502-14. doi: 10.1002/eji.200939069.

7.

Current vaccine adjuvants: an overview of a diverse class.

Kensil CR, Mo AX, Truneh A.

Front Biosci. 2004 Sep 1;9:2972-88. Review.

PMID:
15353330
8.

Detection and consequences of recombinant protein isoforms: implications for biological potency.

Federici MM, Venkat K, Bam N, Patel K, Dal Monte PR, Fernie B, Hensley P, Carr S, Baldoni J, Truneh A, Erickson J.

Dev Biol (Basel). 2003;113:53-7; discussion 113-4.

PMID:
14620852
9.
10.

Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity.

Costello RT, Mallet F, Barbarat B, Schiano De Colella JM, Sainty D, Sweet RW, Truneh A, Olive D.

Leukemia. 2003 Dec;17(12):2500-7.

PMID:
14562115
11.

Inhibition of pro-inflammatory cytokine generation by CTLA4-Ig in the skin and colon of mice adoptively transplanted with CD45RBhi CD4+ T cells correlates with suppression of psoriasis and colitis.

Davenport CM, McAdams HA, Kou J, Mascioli K, Eichman C, Healy L, Peterson J, Murphy S, Coppola D, Truneh A.

Int Immunopharmacol. 2002 Apr;2(5):653-72.

PMID:
12013505
12.

CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis.

Mason U, Aldrich J, Breedveld F, Davis CB, Elliott M, Jackson M, Jorgensen C, Keystone E, Levy R, Tesser J, Totoritis M, Truneh A, Weisman M, Wiesenhutter C, Yocum D, Zhu J.

J Rheumatol. 2002 Feb;29(2):220-9.

PMID:
11838838
13.

CD4 mAb induced apoptosis of peripheral T cells: multiparameter subpopulation analysis by flow cytometry using Attractors.

Fishman-Lobell J, Tsui P, Reddy M, DiPrinzio R, Eichman C, Sweet RW, Truneh A.

J Immunol Methods. 2001 Nov 1;257(1-2):71-82.

PMID:
11687240
14.
15.

Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees.

Newman R, Hariharan K, Reff M, Anderson DR, Braslawsky G, Santoro D, Hanna N, Bugelski PJ, Brigham-Burke M, Crysler C, Gagnon RC, Dal Monte P, Doyle ML, Hensley PC, Reddy MP, Sweet RW, Truneh A.

Clin Immunol. 2001 Feb;98(2):164-74.

PMID:
11161972
16.

Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor.

Morel Y, Schiano de Colella JM, Harrop J, Deen KC, Holmes SD, Wattam TA, Khandekar SS, Truneh A, Sweet RW, Gastaut JA, Olive D, Costello RT.

J Immunol. 2000 Oct 15;165(8):4397-404.

17.

Measurement of protein interaction bioenergetics: application to structural variants of anti-sCD4 antibody.

Doyle ML, Brigham-Burke M, Blackburn MN, Brooks IS, Smith TM, Newman R, Reff M, Stafford WF 3rd, Sweet RW, Truneh A, Hensley P, O'Shannessy DJ.

Methods Enzymol. 2000;323:207-30.

PMID:
10944754
18.

Preclinical development of keliximab, a Primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies.

Bugelski PJ, Herzyk DJ, Rehm S, Harmsen AG, Gore EV, Williams DM, Maleeff BE, Badger AM, Truneh A, O'Brien SR, Macia RA, Wier PJ, Morgan DG, Hart TK.

Hum Exp Toxicol. 2000 Apr;19(4):230-43.

PMID:
10918514
19.

Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor.

Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC, McLaughlin MM, Srinivasula SM, Livi GP, Marshall LA, Alnemri ES, Williams WV, Doyle ML.

J Biol Chem. 2000 Jul 28;275(30):23319-25.

20.
21.

Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle.

Chirmule N, Xiao W, Truneh A, Schnell MA, Hughes JV, Zoltick P, Wilson JM.

J Virol. 2000 Mar;74(5):2420-5.

22.

Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4.

Reddy MP, Kinney CA, Chaikin MA, Payne A, Fishman-Lobell J, Tsui P, Dal Monte PR, Doyle ML, Brigham-Burke MR, Anderson D, Reff M, Newman R, Hanna N, Sweet RW, Truneh A.

J Immunol. 2000 Feb 15;164(4):1925-33.

23.

Repeated administration of adenoviral vectors in lungs of human CD4 transgenic mice treated with a nondepleting CD4 antibody.

Chirmule N, Truneh A, Haecker SE, Tazelaar J, Gao Gp, Raper SE, Hughes JV, Wilson JM.

J Immunol. 1999 Jul 1;163(1):448-55.

24.

Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth.

Harrop JA, McDonnell PC, Brigham-Burke M, Lyn SD, Minton J, Tan KB, Dede K, Spampanato J, Silverman C, Hensley P, DiPrinzio R, Emery JG, Deen K, Eichman C, Chabot-Fletcher M, Truneh A, Young PR.

J Biol Chem. 1998 Oct 16;273(42):27548-56.

25.

Antibodies to TR2 (herpesvirus entry mediator), a new member of the TNF receptor superfamily, block T cell proliferation, expression of activation markers, and production of cytokines.

Harrop JA, Reddy M, Dede K, Brigham-Burke M, Lyn S, Tan KB, Silverman C, Eichman C, DiPrinzio R, Spampanato J, Porter T, Holmes S, Young PR, Truneh A.

J Immunol. 1998 Aug 15;161(4):1786-94.

27.
28.

A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4.

Anderson D, Chambers K, Hanna N, Leonard J, Reff M, Newman R, Baldoni J, Dunleavy D, Reddy M, Sweet R, Truneh A.

Clin Immunol Immunopathol. 1997 Jul;84(1):73-84.

PMID:
9191886
29.

A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation.

Kwon BS, Tan KB, Ni J, Oh KO, Lee ZH, Kim KK, Kim YJ, Wang S, Gentz R, Yu GL, Harrop J, Lyn SD, Silverman C, Porter TG, Truneh A, Young PR.

J Biol Chem. 1997 May 30;272(22):14272-6.

30.

Characterization of CD4-gp120 activation intermediates during human immunodeficiency virus type 1 syncytium formation.

Hart TK, Truneh A, Bugelski PJ.

AIDS Res Hum Retroviruses. 1996 Sep 20;12(14):1305-13.

PMID:
8891109
31.

Simple differentiation between core-fucosylated and nonfucosylated glycans by capillary electrophoresis.

Okafo GN, Burrow LM, Neville W, Truneh A, Smith RA, Reff M, Camilleri P.

Anal Biochem. 1996 Aug 15;240(1):68-74.

PMID:
8811881
32.
33.

Two distinct intracytoplasmic regions of the T-cell adhesion molecule CD28 participate in phosphatidylinositol 3-kinase association.

Pagès F, Ragueneau M, Klasen S, Battifora M, Couez D, Sweet R, Truneh A, Ward SG, Olive D.

J Biol Chem. 1996 Apr 19;271(16):9403-9.

34.

Differential recognition by CD28 of its cognate counter receptors CD80 (B7.1) and B70 (B7.2): analysis by site directed mutagenesis.

Truneh A, Reddy M, Ryan P, Lyn SD, Eichman C, Couez D, Hurle MR, Sekaly RP, Olive D, Sweet R.

Mol Immunol. 1996 Feb;33(3):321-34.

PMID:
8649453
35.
36.

CD28 signal transduction pathways. A comparison of B7-1 and B7-2 regulation of the map kinases: ERK2 and Jun kinases.

Nunes JA, Battifora M, Woodgett JR, Truneh A, Olive D, Cantrell DA.

Mol Immunol. 1996 Jan;33(1):63-70.

PMID:
8604225
37.

Comparison of CD28-B7.1 and B7.2 functional interaction in resting human T cells: phosphatidylinositol 3-kinase association to CD28 and cytokine production.

Ghiotto-Ragueneau M, Battifora M, Truneh A, Waterfield MD, Olive D.

Eur J Immunol. 1996 Jan;26(1):34-41.

PMID:
8566081
38.

Identification of residues in the V domain of CD80 (B7-1) implicated in functional interactions with CD28 and CTLA4.

Fargeas CA, Truneh A, Reddy M, Hurle M, Sweet R, Sékaly RP.

J Exp Med. 1995 Sep 1;182(3):667-75.

39.

Role of intra- and extracellular calcium in histamine release from rat peritoneal mast cells. 1981.

Pearce FL, Ennis M, Truneh A, White JR.

Agents Actions. 1994 Dec;43(3-4):144-7; discussion 148. No abstract available.

PMID:
7537009
40.

Pyridinyl imidazoles inhibit the inflammatory phase of delayed type hypersensitivity reactions without affecting T-dependent immune responses.

Reddy MP, Webb EF, Cassatt D, Maley D, Lee JC, Griswold DE, Truneh A.

Int J Immunopharmacol. 1994 Oct;16(10):795-804.

PMID:
7843851
41.

The role of p21ras in CD28 signal transduction: triggering of CD28 with antibodies, but not the ligand B7-1, activates p21ras.

Nunès JA, Collette Y, Truneh A, Olive D, Cantrell DA.

J Exp Med. 1994 Sep 1;180(3):1067-76.

42.

Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling.

Pagès F, Ragueneau M, Rottapel R, Truneh A, Nunes J, Imbert J, Olive D.

Nature. 1994 May 26;369(6478):327-9. Erratum in: Nature 1994 Jul 14;370(6485):157.

PMID:
8183372
43.

Structures of an HIV and MHC binding fragment from human CD4 as refined in two crystal lattices.

Ryu SE, Truneh A, Sweet RW, Hendrickson WA.

Structure. 1994 Jan 15;2(1):59-74.

PMID:
8075984
44.

Functional expression of human CD28 in murine T cell hybridomas.

Couez D, Pagès F, Ragueneau M, Nunès J, Klasen S, Mawas C, Truneh A, Olive D.

Mol Immunol. 1994 Jan;31(1):47-57.

PMID:
8302298
45.

Bicyclic imidazoles as a novel class of cytokine biosynthesis inhibitors.

Lee JC, Badger AM, Griswold DE, Dunnington D, Truneh A, Votta B, White JR, Young PR, Bender PE.

Ann N Y Acad Sci. 1993 Nov 30;696:149-70. Review. No abstract available.

PMID:
8109825
46.

Oligodeoxynucleotides interact with recombinant CD4 at multiple sites.

Yakubov L, Khaled Z, Zhang LM, Truneh A, Vlassov V, Stein CA.

J Biol Chem. 1993 Sep 5;268(25):18818-23.

47.

Inhibition of CD44, CD45 and LFA-3 mediated cytokine release from human monocytes by SK&F 86002 and pentoxifylline.

Prabhakar U, Lipshutz D, Truneh A.

Int J Immunopharmacol. 1993 Feb;15(2):205-9.

PMID:
7682199
48.

Serum levels and receptor expression of tumor necrosis factor-alpha following human allogeneic and autologous bone marrow transplantation.

Robinet E, Ibrahim A, Truneh A, Ostronoff M, Mishal Z, Zambon E, Gay F, Hayat M, Pico JL, Chouaib S.

Transplantation. 1992 Mar;53(3):574-9.

PMID:
1312753
49.

Immunization with soluble murine CD4 induces an anti-self antibody response without causing impairment of immune function.

Cassatt DR, Sweet RW, Arthos JA, Truneh A.

J Immunol. 1991 Sep 1;147(5):1470-6.

PMID:
1880414
50.

CD4: its structure, role in immune function and AIDS pathogenesis, and potential as a pharmacological target.

Sweet RW, Truneh A, Hendrickson WA.

Curr Opin Biotechnol. 1991 Aug;2(4):622-33. Review.

PMID:
1367682

Supplemental Content

Loading ...
Support Center